Cytodyn Inc (CYDY) 1.0000 $CYDY
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Thu Jul 31, 7:21AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced positive interim results from its Phase 2b treatment substitution study. The Company will hold an investment community conference call on August 4, 2014, at 9:00 a.m. PT to discuss the trial's protocol, clinical results, and anticipated path forward, as well as to address questions from the call's participants.
CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Wed Jul 30, 8:52PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Monday, August 4, 2014 at 9:00 a.m. PT to discuss the interim results from its ongoing Phase 2b treatment substitution study in patients with HIV.
OTC Market Trading List: CytoDyn, Inc. Alliance Semiconductor Corp, Bayside Corp, In Ovations Holdings, Novagant Corp.
PR Newswire Europe - Fri Jun 20, 7:52AM CDT
LONDON, June 20, 2014 /PRNewswire/ --
CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy
Business Wire - Wed Mar 19, 7:05AM CDT
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company will host a live conference call and webcast with the investment community on Tuesday, March 25, 2014 at 1:30 p.m. PT to provide an update on the Company's clinical development strategy for lead product candidate, PRO 140, including progress with its preparations for its treatment substitution Phase 2b study in patients with Human Immunodeficiency Virus (HIV). PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells, and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
CytoDyn Files Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV
Close-Up Media - Thu Feb 20, 11:36PM CST
CytoDyn Inc., a biotechnology company focusing on the development of new therapies for combating infection with immune deficiency viruses, said that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).
CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140
Business Wire - Tue Jan 28, 7:05AM CST
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company plans to expand its clinical development program for PRO 140 and signed an agreement with Amarex Clinical Research LLC to prepare two Phase 2b clinical trial protocols to explore two additional therapeutic indications for its lead product candidate. One of the new protocols is expected to be completed in the first quarter of 2014 and the second protocol early in the second quarter of 2014. After submission of the Phase 2b clinical trial protocols to the U.S. Food and Drug Administration (FDA), the Company and Amarex will work with the FDA to obtain approval to commence the trials.
CytoDyn to Webcast Presentation at Biotech Showcase 2014 in San Francisco on Monday, January 13, at 2:30 PM Pacific
Business Wire - Wed Jan 08, 7:04AM CST
---Presentation Will Focus on Company's Strategic Priorities and Development Plans for Lead Product Candidate PRO 140-
CytoDyn Announces FDA Approval of Patient Screening for Phase 2b Study with Lead Product Candidate PRO 140 for the Treatment of HIV Type 1
Business Wire - Tue Jan 07, 3:41PM CST
--Study being conducted by leading HIV expert, Jeffrey M. Jacobson, M.D., at Drexel University
OTC Daily Alert Stock Watch - CytoDyn (OTCQB: CYDY)
WorldStockWire - Thu Aug 15, 10:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CytoDyn Inc names Anthony D. Caracciolo as board chair
M2 - Tue Jun 18, 6:13AM CDT
Biotechnology company CytoDyn Inc (OTC QB:CYDY) revealed on Monday the appointment of Anthony D. Caracciolo as chairman of the board of directors with immediate effect.
CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
Business Wire - Mon Jun 17, 3:52PM CDT
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that Anthony D. Caracciolo has been appointed Chairman of the Board of Directors effective June 17, 2013. Past Chairman, Gregory A. Gould, will remain a member of the Board of Directors and continue to serve as Chair of the Audit Committee.
CytoDyn Announces Important Milestone Achieved to Initiate Phase IIb Studies
Business Wire - Mon Apr 29, 3:11PM CDT
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for the treatment of human immunodeficiency virus (HIV) infection, announced that CytoDyn Inc. and Drexel University have entered into a contract with Ajinomoto Althea, Inc. to formulate CytoDyn's PRO 140 bulk drug substance through a "fill and finish" process resulting in clinical-ready vials to advance its two NIH-funded Phase IIb studies. These trials will be conducted by Drexel University and are funded by over $10 million in grants from the National Institute of Health (NIH). Ajinomoto Althea, Inc. is a contract development and manufacturing company based in San Diego, California.
CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference
Business Wire - Wed Feb 27, 8:00AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology at the BIOCOM Global Life Sciences Partnering Conference at the Lodge in Torrey Pines, La Jolla, California.
CytoDyn Announces Collaboration with Dr. Bruce Torbett, The Scripps Research Institute, to study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV Infection
Business Wire - Tue Feb 26, 10:29AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a research collaboration with Dr. Bruce Torbett of The Scripps Research Institute to study CytoDyn's experimental humanized anti-CCR5 antibody PRO 140 in a pre-exposure prophylaxis (PrEP) model of HIV infection.
CytoDyn Announces Investor Update Conference Call on Friday, February 22
Business Wire - Tue Feb 19, 8:00AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will conduct a shareholder update conference call at 10:00 AM PST on Friday, February 22, 2013.
CytoDyn to Attend 31st Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 07, 6:51AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology during the 31st Annual J.P. Morgan Healthcare Conference on January 9, 2013 at 3:15 PM PT. More information regarding the conference can be found at http://www.ebdgroup.com/bts/index.php.
CytoDyn Appoints Former Ambassador to Bahrain as Middle East Business Consultant
Business Wire - Wed Jan 02, 7:52AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it has entered into a consulting agreement with former U.S. Ambassador Sam Zakhem.
CytoDyn Elects Two New Directors and Appoints New Chief Financial Officer
Business Wire - Tue Dec 18, 8:17AM CST
CytoDyn Inc. ("CytoDyn" (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced the election of Michael Nobel, Ph.D., and Allan M. Green, M.D., Ph.D., J.D., to the company's Board of Directors at its annual shareholders meeting held on December 12, 2012. CytoDyn also announced the appointment of Michael D. Mulholland as the company's new Chief Financial Officer, Treasurer and Corporate Secretary, effective December 13, 2012.
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Thu Jul 31, 7:21AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced positive interim results from its Phase 2b treatment substitution study. The Company will hold an investment community conference call on August 4, 2014, at 9:00 a.m. PT to discuss the trial's protocol, clinical results, and anticipated path forward, as well as to address questions from the call's participants.
CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Wed Jul 30, 8:52PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Monday, August 4, 2014 at 9:00 a.m. PT to discuss the interim results from its ongoing Phase 2b treatment substitution study in patients with HIV.
OTC Market Trading List: CytoDyn, Inc. Alliance Semiconductor Corp, Bayside Corp, In Ovations Holdings, Novagant Corp.
PR Newswire Europe - Fri Jun 20, 7:52AM CDT
LONDON, June 20, 2014 /PRNewswire/ --
CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy
Business Wire - Wed Mar 19, 7:05AM CDT
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company will host a live conference call and webcast with the investment community on Tuesday, March 25, 2014 at 1:30 p.m. PT to provide an update on the Company's clinical development strategy for lead product candidate, PRO 140, including progress with its preparations for its treatment substitution Phase 2b study in patients with Human Immunodeficiency Virus (HIV). PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells, and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
CytoDyn Files Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV
Close-Up Media - Thu Feb 20, 11:36PM CST
CytoDyn Inc., a biotechnology company focusing on the development of new therapies for combating infection with immune deficiency viruses, said that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).
CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140
Business Wire - Tue Jan 28, 7:05AM CST
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company plans to expand its clinical development program for PRO 140 and signed an agreement with Amarex Clinical Research LLC to prepare two Phase 2b clinical trial protocols to explore two additional therapeutic indications for its lead product candidate. One of the new protocols is expected to be completed in the first quarter of 2014 and the second protocol early in the second quarter of 2014. After submission of the Phase 2b clinical trial protocols to the U.S. Food and Drug Administration (FDA), the Company and Amarex will work with the FDA to obtain approval to commence the trials.
CytoDyn to Webcast Presentation at Biotech Showcase 2014 in San Francisco on Monday, January 13, at 2:30 PM Pacific
Business Wire - Wed Jan 08, 7:04AM CST
---Presentation Will Focus on Company's Strategic Priorities and Development Plans for Lead Product Candidate PRO 140-
CytoDyn Announces FDA Approval of Patient Screening for Phase 2b Study with Lead Product Candidate PRO 140 for the Treatment of HIV Type 1
Business Wire - Tue Jan 07, 3:41PM CST
--Study being conducted by leading HIV expert, Jeffrey M. Jacobson, M.D., at Drexel University
OTC Daily Alert Stock Watch - CytoDyn (OTCQB: CYDY)
WorldStockWire - Thu Aug 15, 10:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CytoDyn Inc names Anthony D. Caracciolo as board chair
M2 - Tue Jun 18, 6:13AM CDT
Biotechnology company CytoDyn Inc (OTC QB:CYDY) revealed on Monday the appointment of Anthony D. Caracciolo as chairman of the board of directors with immediate effect.
CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
Business Wire - Mon Jun 17, 3:52PM CDT
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that Anthony D. Caracciolo has been appointed Chairman of the Board of Directors effective June 17, 2013. Past Chairman, Gregory A. Gould, will remain a member of the Board of Directors and continue to serve as Chair of the Audit Committee. CytoDyn Announces Important Milestone Achieved to Initiate Phase IIb Studies
Business Wire - Mon Apr 29, 3:11PM CDT
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for the treatment of human immunodeficiency virus (HIV) infection, announced that CytoDyn Inc. and Drexel University have entered into a contract with Ajinomoto Althea, Inc. to formulate CytoDyn's PRO 140 bulk drug substance through a "fill and finish" process resulting in clinical-ready vials to advance its two NIH-funded Phase IIb studies. These trials will be conducted by Drexel University and are funded by over $10 million in grants from the National Institute of Health (NIH). Ajinomoto Althea, Inc. is a contract development and manufacturing company based in San Diego, California. CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference
Business Wire - Wed Feb 27, 8:00AM CST
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology at the BIOCOM Global Life Sciences Partnering Conference at the Lodge in Torrey Pines, La Jolla, California. CytoDyn Announces Collaboration with Dr. Bruce Torbett, The Scripps Research Institute, to study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV Infection
Business Wire - Tue Feb 26, 10:29AM CST
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a research collaboration with Dr. Bruce Torbett of The Scripps Research Institute to study CytoDyn's experimental humanized anti-CCR5 antibody PRO 140 in a pre-exposure prophylaxis (PrEP) model of HIV infection. CytoDyn Announces Investor Update Conference Call on Friday, February 22
Business Wire - Tue Feb 19, 8:00AM CST
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will conduct a shareholder update conference call at 10:00 AM PST on Friday, February 22, 2013. CytoDyn to Attend 31st Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 07, 6:51AM CST
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology during the 31st Annual J.P. Morgan Healthcare Conference on January 9, 2013 at 3:15 PM PT. More information regarding the conference can be found at http://www.ebdgroup.com/bts/index.php. CytoDyn Appoints Former Ambassador to Bahrain as Middle East Business Consultant
Business Wire - Wed Jan 02, 7:52AM CST
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it has entered into a consulting agreement with former U.S. Ambassador Sam Zakhem. CytoDyn Elects Two New Directors and Appoints New Chief Financial Officer
Business Wire - Tue Dec 18, 8:17AM CST
CytoDyn Inc. ("CytoDyn"
(OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced the election of Michael Nobel, Ph.D., and Allan M. Green, M.D., Ph.D., J.D., to the company's Board of Directors at its annual shareholders meeting held on December 12, 2012. CytoDyn also announced the appointment of Michael D. Mulholland as the company's new Chief Financial Officer, Treasurer and Corporate Secretary, effective December 13, 2012. 
